q$%~ Sy %QE3v=

Bruton’s tyrosine kinase (BTK) is a component of the B-cell receptor (BCR) signaling pathway and is an important regulator of cell proliferation and cell survival in various B cell malignancies including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström’s macroglobulinemia (WM) and marginal zone lymphoma (MZL). BTK inhibitors (BTKi) block BCR-induced BTK activation and its downstream signaling, leading to growth inhibition and cell death in B-cells.³

Zanubrutinib is an orally active inhibitor that covalently binds cysteine 481 in the adenosine triphosphate (ATP) binding pocket of BTK leading to irreversible inactivation of the enzyme.^E Zanubrutinib was designed to minimize off-target inhibition of TEC and EGFR family kinases. In pre-clinical studies zanubrutinib was shown to have high selectivity for BTK. BTK inhibitors that are more specific may be associated with fewer treatment-related toxicities.^E

For a complete list of zanubrutinib monotherapy and combination clinical trials, view the C]?]#9CJ]4K igKsgh).

Please see full jR 8W,4mWaKaiy [usU|}Zb$Uu Lt[ 0bQ1yn1nn Lpy-[)b]L-p rX 2**cBTvP Aw0w.

J=Z=v=0Y=g

1. Tam, C. S. (S Z*. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. L]gg\ 2019;134:851–859.
2. Pal Singh, S., Dammeijer, F. & Hendriks, R. W. Role of Bruton’s tyrosine kinase in B cells and malignancies. 7}@. B{s%j? 2018;17:57.